While tumor gene expression analyses have become widely available only in recent years, routine immunohistochemistry (IHC) evaluation of the expression of estrogen receptor (ER), progesterone receptor (PR), and HER2 has been universally adopted to assess susceptibility to endocrine and HER2-directed treatment. This evidence concerns the gene PGR and neoplasm.